Company Overview

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

  • Name

    Zoetis Inc.

  • CEO

    Ms. Kristin C. Peck

  • Website

    www.zoetis.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1952

Profile

  • Market Cap

    $85.73B

  • EV

    $90.92B

  • Shares Out

    453.05M

  • Revenue

    $8,915M

  • Employees

    14,100

Margins

  • Gross

    70.01%

  • EBITDA

    40.89%

  • Operating

    36.09%

  • Pre-Tax

    32.46%

  • Net

    26.29%

  • FCF

    23.59%

Returns (5Yr Avg)

  • ROA

    14.78%

  • ROTA

    122.05%

  • ROE

    51.23%

  • ROCE

    23.85%

  • ROIC

    23.27%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $216.32

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $1,574M

  • Net Debt

    $5,200M

  • Debt/Equity

    1.37

  • EBIT/Interest

    13.69

Growth (CAGR)

  • Rev 3Yr

    6.35%

  • Rev 5Yr

    8.08%

  • Rev 10Yr

    6.81%

  • Dil EPS 3Yr

    8.52%

  • Dil EPS 5Yr

    12.5%

  • Dil EPS 10Yr

    17.12%

  • Rev Fwd 2Yr

    7.13%

  • EBITDA Fwd 2Yr

    8.42%

  • EPS Fwd 2Yr

    10.06%

  • EPS LT Growth Est

    8.96%

Dividends

  • Yield

  • Payout

    31.55%

  • DPS

    $1.61

  • DPS Growth 3Yr

    21.49%

  • DPS Growth 5Yr

    22.71%

  • DPS Growth 10Yr

    19.4%

  • DPS Growth Fwd 2Yr

    10.74%

NYSE:ZTS